Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1995-6-21
|
pubmed:abstractText |
A variety of tumors are potentially immunogenic but do not stimulate an effective antitumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. In this regard, we recently reported that a human melanoma cell line (sMC) expressing MHC class II, was able to induce clonal anergy in a specific, MHC-restricted CD-4+ T cell clone (sTC3). We used this system to investigate the influence of interleukin (IL)-12 on induction of this T cell unresponsiveness. The presence of 10 to 100 U IL-12 during the induction phase of anergy leads to a primary proliferative response of sTC3, which was significantly higher than that induced by IL-12 alone; however, in the absence of IL-12 no proliferation was seen during the induction of anergy. Subsequent optimal stimulation of IL-12 treated cells, but not of those cultured without IL-12, led to substantial IL-2 production and cell proliferation. This indicates that induction of the unresponsive state could be inhibited by IL-12. In addition, we have recently demonstrated that anergic T cell clones can produce high amounts of IL-10 and that this event was correlated with their impaired ability to produce IL-2. This marked induction of IL-10 can be suppressed if IL-12 is present during initiation of unresponsiveness. However, IL-12 was not able to prime the T cell clone, sTC3, to become resistant against the anergizing stimulus, as this cytokine was only effective when present at the time of anergy induction.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0906-6705
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
283-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7538408-Antigens, CD80,
pubmed-meshheading:7538408-CD4-Positive T-Lymphocytes,
pubmed-meshheading:7538408-Cells, Cultured,
pubmed-meshheading:7538408-Clone Cells,
pubmed-meshheading:7538408-DNA, Complementary,
pubmed-meshheading:7538408-Humans,
pubmed-meshheading:7538408-Immune Tolerance,
pubmed-meshheading:7538408-Interleukin-12,
pubmed-meshheading:7538408-Lymphocyte Activation,
pubmed-meshheading:7538408-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:7538408-Melanoma,
pubmed-meshheading:7538408-Recombinant Proteins,
pubmed-meshheading:7538408-Transfection,
pubmed-meshheading:7538408-Tumor Cells, Cultured
|
pubmed:year |
1994
|
pubmed:articleTitle |
Prevention of anergy induction in cloned T cells by interleukin 12.
|
pubmed:affiliation |
Department of Dermatology, University of Würzburg, Germany.
|
pubmed:publicationType |
Journal Article
|